文献速递疼痛医学

利多卡因输注治疗难治性慢性偏头痛的回顾性分析

Lidocaine infusions for refractory chronic migraine: a retrospective analysis.
PubMed 文献 · Reg Anesth Pain Med · 2022-01-01

本研究回顾性分析了609例难治性慢性偏头痛患者的住院利多卡因连续多日输注记录。结论认为利多卡因输注可能与短期和中期疼痛缓解相关,需前瞻性研究证实。

要点

  • 利多卡因连续多日输注可使难治性慢性偏头痛患者出院时疼痛评分显著降低。
  • 常见不良反应为恶心和呕吐,均为轻度。

核心结论

  • 利多卡因输注可能与难治性慢性偏头痛的短期和中期疼痛缓解相关,需前瞻性研究确认。

研究设计与样本

  • 回顾性分析,共纳入609例符合条件的住院患者(来自832例次连续多日利多卡因输注记录)。
  • 患者均符合难治性慢性偏头痛标准,住院期间同时接受酮咯酸、镁剂、双氢麦角胺、甲泼尼龙和神经阻滞剂等其他偏头痛药物治疗。

主要发现

  • 疼痛评分中位数从基线7.0(5.0-8.0)降至出院时1.0(0.0-3.0),p<0.001;87.8%的患者为急性应答者。
  • 头痛天数(N=266)从基线26.8±3.9降至出院后门诊随访时的22.5±8.3(p<0.001)。
  • 恶心和呕吐是最常见的不良反应,均为轻度。

临床怎么用

  • 对于难治性慢性偏头痛患者,可考虑连续多日利多卡因输注以快速打破疼痛周期。
  • 治疗期间需监测恶心、呕吐等不良反应,并注意其均为轻度。

局限性

  • 为回顾性分析,证据级别有限,需前瞻性研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with refractory chronic migraine have poor quality of life. Intravenous infusions are indicated to rapidly 'break the cycle' of pain. Lidocaine infusions may be effective but evidence is limited. METHODS: The records of 832 hospital admissions involving continuous multiday lidocaine infusions for migraine were reviewed. All patients met criteria for refractory chronic migraine. During hospitalization, patients received additional migraine medications including ketorolac, magnesium, dihydroergotamine, methylprednisolone, and neuroleptics. The primary outcome was change in headache pain from baseline to hospital discharge. Secondary outcomes measured at the post-discharge office visit (25-65 days after treatment) included headache pain and the number of headache days, and percentage of sustained responders. Percentage of acute responders, plasma lidocaine levels, and adverse drug effects were also determined. RESULTS: In total, 609 patient admissions met criteria. The mean age was 46±14 years; 81.1% were female. Median pain rating decreased from baseline of 7.0 (5.0-8.0) to 1.0 (0.0-3.0) at end of hospitalization (p<0.001); 87.8% of patients were acute responders. Average pain (N=261) remained below baseline at office visit 1 (5.5 (4.0-7.0); p<0.001). Forty-three percent of patients were sustained responders at 1 month. Headache days (N=266) decreased from 26.8±3.9 at baseline to 22.5±8.3 at the post-discharge office visit (p<0.001). Nausea and vomiting were the most common adverse drug effects and all were mild. CONCLUSION: Lidocaine infusions may be associated with short-term and medium-term pain relief in refractory chronic migraine. Prospective studies should confirm these results.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Schwenk ES, Walter A, Torjman MC, et al. Lidocaine infusions for refractory chronic migraine: a retrospective analysis. Reg Anesth Pain Med. 2022. PMID: 35609890. doi:10.1136/rapm-2021-103180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。